Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Random-effects models were used for calculating mean differences (MDs) for the continuous outcomes and relative risks (RRs) for the categorical outcomes
Asia-Pacific Asia-Pacific captured 19% share of the Liraglutide and Semaglutide market in 2024 and is projected to be the fastest-growing region during the forecast period
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (under the brand name Ozempic), chronic weight management (as Wegovy), and cardiovascular risk reduction
Glutathione S-transferase tissue profiling by reporter peptide monitoring
DISCLAIMERS The authors have no competing interests to declare
US$ 22.85
US$ 27.83
US$ 28.52
